ArticleClinics in shoulder and elbow2026
Hemophilia increases risk of bleeding and thromboembolism after total shoulder arthroplasty.
Article in Clinics in shoulder and elbow, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHemophilia, including hemophilia A, hemophilia B, and related coagulation disorders, poses unique perioperative challenges in total shoulder arthroplasty (TSA). Factor replacement and postoperative immobilization may paradoxically increase thromboembolic risk, yet the literature defining venous thromboembolism (VTE) and other complications in this population is limited. We aimed to characterize 90-day postoperative outcomes among patients with hemophilia undergoing TSA.
methodsA multicenter electronic health record database (TriNetX Global) was retrospectively analyzed to identify patients undergoing TSA between December 2005 and December 2025. Patients with hemophilia were compared to propensity-matched controls based on relevant comorbidities. Primary outcomes included 90-day rates of readmission, periprosthetic joint infection (PJI), revision surgery, bleeding complications, and VTE. Secondary outcomes included deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, pneumonia, acute kidney injury (AKI), and urinary tract infection (UTI). Odds ratios with 95% CIs were calculated. P-value <0.05 was considered statistically significant.
resultsCompared with matched controls, patients with hemophilia had significantly higher rates of readmission and revision surgery. They also demonstrated increased risk of bleeding complications and thromboembolic events, including DVT, PE, VTE, and stroke. Higher rates of postoperative medical complications, including pneumonia, AKI, and UTI, as well as greater postoperative opioid prescription utilization were observed. Rates of PJI did not differ between groups.
conclusionsPatients with hemophilia are at significantly increased risk of thromboembolic complications and revision surgery following TSA. Prospective studies evaluating preoperative optimization and management of modifiable VTE risk factors are warranted. Level of evidence: III.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.